Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
World Journal of Surgery|May 18, 2023
Umbilical Hernia Repair in Patients with Cirrhosis and in Patients with Severe Comorbidities-A Nationwide Cohort StudyChristian Snitkjær, Mette W Christoffersen, Lise Lotte Gluud, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 20, 2025
The heterogeneity of cirrhosis - systemically assessed endotypes described by fibrosis, apoptosis, and immunoregulatory-related biomarkersEmilie Toft Skovgaard, Andressa de Zawadzki, Nina Kimer, et al.
World Journal of Gastroenterology|April 25, 2018
Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patientsAgnete Nordheim Riedel, Nina Kimer, Anne-Sofie Houlberg Jensen, et al.
Plos One|March 14, 2022
The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trialNina Kimer, Mads Meldgaard, Ole Hamberg, et al.
Hepatology (Baltimore, Md.)|October 25, 2016
Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trialNina Kimer, Julie Steen Pedersen, Troels Malte Busk, et al.
Practical Laboratory Medicine|May 7, 2026
LC-MS/MS of PEth in whole blood: implementation in routine clinical chemistryJakob Albrethsen, Ditte Hermann, Ninna Hahn Tougaard, et al.
Ugeskrift for Laeger|November 3, 2023
Tobias Malte Larsen, Malene Barfod O'Connell, Ane Teisner, et al.
Medicina (Kaunas, Lithuania)|October 30, 2020
Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-SeriesNina Kimer, Agnete Nordheim Riedel, Lise Hobolth, et al.
Metabolic Brain Disease|July 17, 2024
Portosystemic Hepatic Encephalopathy Scores (PHES) differ between Danish and German healthy populations despite their geographical and cultural similaritiesMette Munk Lauridsen, Lea Ladegaard Grønkjær, Jeppe Holm Atkins, et al.
Plos One|September 6, 2018
No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trialNina Kimer, Natasja Stæhr Gudmann, Julie Steen Pedersen, et al.
Pageof 6